Milestone Pharmaceuticals Inc. Investment Income, Interest
Milestone Pharmaceuticals Inc. (MIST) reported Investment Income, Interest of $1.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-12
- Milestone Pharmaceuticals Inc. investment income, interest for the quarter ending 2026-06-30 was $1.74M, a 237.40% increase year-over-year.
- Milestone Pharmaceuticals Inc. investment income, interest for the quarter ending 2026-03-31 was $1.73M, a 148.49% increase year-over-year.
- Milestone Pharmaceuticals Inc. investment income, interest for the quarter ending 2025-12-31 was $833.00K, a 7.85% decline year-over-year.
- Milestone Pharmaceuticals Inc. investment income, interest for the quarter ending 2025-09-30 was $874.00K, a 19.07% decline year-over-year.
- Milestone Pharmaceuticals Inc. investment income, interest for fiscal 2025 was $2.92M, a 29.88% decline from fiscal 2024.
- Milestone Pharmaceuticals Inc. investment income, interest for fiscal 2024 was $4.16M, a 4.97% increase from fiscal 2023.
- Milestone Pharmaceuticals Inc. investment income, interest for fiscal 2023 was $3.97M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.74M 10-Q · filed 2026-08-12 | $3.47M 10-Q · filed 2026-08-12 | $4.31M derived: sum of 3 quarters · filed 2026-08-12 | $5.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.73M 10-Q · filed 2026-05-13 | $2.56M derived: sum of 2 quarters · filed 2026-05-13 | $3.44M derived: sum of 3 quarters · filed 2026-05-13 | $3.96M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $833.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $1.71M derived: sum of 2 quarters · filed 2026-03-20 | $2.22M derived: sum of 3 quarters · filed 2026-08-12 | $2.92M 10-K · filed 2026-03-20 |
| 2025-09-30 | $874.00K 10-Q · filed 2025-11-12 | $1.39M derived: sum of 2 quarters · filed 2026-08-12 | $2.09M 10-Q · filed 2025-11-12 | $2.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $516.00K 10-Q · filed 2026-08-12 | $1.21M 10-Q · filed 2026-08-12 | $2.12M derived: sum of 3 quarters · filed 2026-08-12 | $3.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $697.00K 10-Q · filed 2026-05-13 | $1.60M derived: sum of 2 quarters · filed 2026-05-13 | $2.68M derived: sum of 3 quarters · filed 2026-05-13 | $3.87M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $1.98M derived: sum of 2 quarters · filed 2026-03-20 | $3.17M derived: sum of 3 quarters · filed 2026-03-20 | $4.16M 10-K · filed 2026-03-20 |
| 2024-09-30 | $1.08M 10-Q · filed 2025-11-12 | $2.27M derived: sum of 2 quarters · filed 2025-11-12 | $3.26M 10-Q · filed 2025-11-12 | $4.31M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.19M 10-Q · filed 2025-08-12 | $2.18M 10-Q · filed 2025-08-12 | $3.23M derived: sum of 3 quarters · filed 2025-08-12 | $4.35M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $994.00K 10-Q · filed 2025-05-14 | $2.04M derived: sum of 2 quarters · filed 2025-05-14 | $3.16M derived: sum of 3 quarters · filed 2025-05-14 | $4.37M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.17M derived: sum of 2 quarters · filed 2025-03-13 | $3.38M derived: sum of 3 quarters · filed 2025-03-13 | $3.97M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.12M 10-Q · filed 2024-11-12 | $2.33M derived: sum of 2 quarters · filed 2024-11-12 | $2.92M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.21M 10-Q · filed 2024-08-08 | $1.80M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $585.00K 10-Q · filed 2024-05-13 | |||
| 2022-09-30 | $474.00K 10-Q · filed 2023-11-13 | $632.00K derived: sum of 2 quarters · filed 2023-11-13 | $672.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $158.00K 10-Q · filed 2023-08-10 | $198.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |